Reaction Biology, 4HF Biotec offer new cell-based services October 19, 2020 -- Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
CHMP recommends Alnylam's RNAi therapeutic for approval October 16, 2020 -- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) posted a positive opinion recommending approval for Alnylam Pharmaceutical's lumasiran, an investigational RNA interference (RNAi) therapeutic for the treatment of primary hyperoxaluria type 1.
Ionis' inhaled antisense drug shows promise as CF treatment October 13, 2020 -- Ionis Pharmaceuticals has released positive data from a clinical trial evaluating IONIS-ENAC-2.5Rx, an investigational antisense medicine designed to reduce expression of epithelial sodium channel in cystic fibrosis (CF) patients.
Oncopeptides moves to file for regulatory approvals October 12, 2020 -- Oncopeptides plans to submit an application for a conditional marketing authorization of melflufen in the European Union, based on the phase II Horizon study in relapsed refractory multiple myeloma.